Advances in the host-directed therapy of tuberculosis

doi:10.19982/j.issn.1000-6621.20240207

Abstract

Abstract:

Host-directed therapy (HDT) is a new adjuvant therapy for tuberculosis, which aims at host cells rather than pathogens via modulating host immune response to combat infections. When combined use of HDT with anti-tuberculosis drugs, it provides benefits to enhance the efficacy of chemotherapy, shorten the treatment duration, decrease immunopathological damage, and prevent the emergence of drug resistance. This paper reviews the common mechanisms of HDT, and summarizes several HDT drug candidates that are currently being studied, in order to provide new insight for developing new and effective anti-tuberculosis therapies.

Key words: Tuberculosis, Immunity, Therapeutic uses, Review literature as topic

CLC Number:

Yan Hongxuan, Yuan Jinfeng, Wang Yilin, Pang Yu, Gao Mengqiu. Advances in the host-directed therapy of tuberculosis[J]. Chinese Journal of Antituberculosis, 2024, 46(10): 1273-1282. doi: 10.19982/j.issn.1000-6621.20240207

Figures/Tables 5

名称	机制	研究阶段	人/动物	参考文献
帕唑帕尼	抑制VEGF,影响肉芽肿	临床前	斑马鱼	[7]
多西环素	抑制MMPs,影响肉芽肿	临床试验Ⅲ期	结核病患者	[8]
伊马替尼	阻断PI3K/Akt/mTOR,促自噬	临床前	小鼠	[9-10]
雷帕霉素	抑制mTOR,促自噬	临床前	小鼠	[11]
依维莫司	抑制mTOR,促自噬	临床试验Ⅱ期	结核病患者	[12]
硝唑尼特	抑制NQO1,促自噬	临床前	细胞	[13]
卡马西平	激活AMPK,促自噬	临床前	小鼠	[14]
氟西汀	促进JNK途径,促自噬	临床前	小鼠	[15]
吉非替尼	抑制p38MAPK,促自噬	临床前	小鼠	[15]
他莫昔芬	促溶酶体输送,促自噬	临床前	斑马鱼	[16]
巴多昔芬	增强ROS产生,促自噬	临床前	细胞	[17]
维生素D3	上调自噬相关基因,促自噬	临床试验Ⅲ期	结核病患者	[18]
维拉帕米	抑制钙离子外排泵Rv1258,促自噬	临床前	细胞	[19-20]
洛哌丁胺	诱导ATG16L1基因的表达,促自噬	临床前	小鼠	[19]
维生素B1	抑制PPAR-γ,增强巨噬细胞杀伤力	临床前	细胞	[21]
霉菌素	抑制PPAR-γ,增强巨噬细胞杀伤力	临床前	小鼠	[22]
二甲双胍	诱导CD8⁺T细胞免疫代谢回路;抑制mTOR,促自噬;调节炎症反应	临床试验Ⅱ期	结核病患者	[23-24]
比阿培南	增强T淋巴细胞对炎症亚群的极化	临床前	小鼠	[25]
氯法齐明	阻断Kv1.3钾通道促进中央记忆型T细胞产生	临床前	小鼠	[11]
沙奎那韦	增加T淋巴细胞的启动和增殖	临床前	细胞	[26]
布洛芬	抑制COX,抑制过度炎症	临床试验Ⅱ期	结核病患者	[27]
阿司匹林	抑制COX,抑制过度炎症	临床试验Ⅱ期	结核病患者	[28]
塞来昔布	抑制COX,抑制过度炎症	临床前	小鼠	[29]
依托考昔	抑制COX,抑制过度炎症	临床试验Ⅰ期	结核病患者	[30]
美洛昔康	抑制COX,抑制过度炎症	临床试验Ⅲ期	结核病患者	[30]
西洛他唑	抑制PDEs,减少巨噬细胞活化和TNF-α表达,抑制过度炎症	临床前	小鼠	[9]
西地那非	抑制PDEs,减少巨噬细胞活化和TNF-α表达,抑制过度炎症	临床前	小鼠	[31]
罗氟司特	抑制PDEs,减少巨噬细胞活化和TNF-α表达,抑制过度炎症	临床前	小鼠	[32]
齐留通	抑制5-LOX,抑制过度炎症	临床前	小鼠	[26]
阿托伐他汀	抑制胆固醇、Rho蛋白合成,抑制过度炎症;诱导自噬	临床试验Ⅱ期	结核病患者	[33-34]
瑞舒伐他汀	抑制胆固醇、Rho蛋白合成,抑制过度炎症;诱导自噬	临床试验Ⅱ期	结核病患者	[33-34]
N-乙酰-L-半胱氨酸乙酯	抑制宿主氧化反应,调节炎症	临床试验Ⅱ期	结核病患者	[35]
舍曲林	抑制Ⅰ型干扰素反应,减轻过度炎症	临床前	小鼠	[36]
依那西普	抑制TNF-α,减轻过度炎症	临床前	小鼠	[37]
托法替尼	抑制JAK,调节炎症	临床前	小鼠	[38]
帕考珠单抗	抗IL-4单克隆抗体,调节炎症	临床试验Ⅱ期	结核病患者	[39]

References 65

[1]	Wallis RS, O’garra A, Sher A, et al. Host-directed immunotherapy of viral and bacterial infections: past, present and future. Nat Rev Immunol, 2023, 23(2):121-133. doi:10.1038/s41577-022-00734-z.
[2]	Huang X, Lowrie DB, Fan XY, et al. Natural products in anti-tuberculosis host-directed therapy. Biomed Pharmacother, 2024, 171:116087. doi:10.1016/j.biopha.2023.116087.
[3]	王丽, 杨恩卓, 沙巍, 等. 结核病免疫治疗的研究进展. 中国防痨杂志, 2022, 44 (10): 1079-1084. doi:10.19982/j.issn.1000-6621.20220194.
[4]	Hawn TR, Shah JA, Kalman D. New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics. Immunol Rev, 2015, 264(1):344-362. doi:10.1111/imr.12255. pmid: 25703571
[5]	Wallis RS, Maeurer M, Mwaba P, et al. Tuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect Dis, 2016, 16(4): e34-e46. doi:10.1016/S1473-3099(16)00070-0.
[6]	Cubillos-Angulo JM, Nogueira BMF, Arriaga MB, et al. Host-directed therapies in pulmonary tuberculosis: Updates on anti-inflammatory drugs. Front Med (Lausanne), 2022, 9:970408. doi:10.3389/fmed.2022.970408.
[7]	Oehlers SH, Cronan MR, Scott NR, et al. Interception of host angiogenic signalling limits mycobacterial growth. Nature, 2015, 517(7536): 612-615. doi:10.1038/nature13967.
[8]	Sabir N, Hussain T, Mangi MH, et al. Matrix metalloproteinases: Expression, regulation and role in the immunopathology of tuberculosis. Cell Prolif, 2019, 52(4): e12649. doi:10.1111/cpr.12649.
[9]	Cleverley TL, Peddineni S, Guarner J, et al. The host-directed therapeutic imatinib mesylate accelerates immune responses to Mycobacterium marinum infection and limits pathology associated with granulomas. PLoS Pathog, 2023, 19(5): e1011387. doi:10.1371/journal.ppat.1011387.
[10]	关艳敏, 白大鹏. 结核病宿主导向治疗药物机制的研究进展. 继续医学教育, 2022, 36(10):157-160. doi:10.3969/j.issn.1004-6763.2022.10.040.
[11]	Singh DK, Bhaskar A, Pahuja I, et al. Cotreatment With Clofazimine and Rapamycin Eliminates Drug-Resistant Tuberculosis by Inducing Polyfunctional Central Memory T-Cell Responses. J Infect Dis, 2023, 228(9): 1166-1178. doi:10.1093/infdis/jiad214.
[12]	Cerni S, Shafer D, To K, et al. Investigating the Role of Everolimus in mTOR Inhibition and Autophagy Promotion as a Potential Host-Directed Therapeutic Target in Mycobacterium tuberculosis Infection. J Clin Med, 2019, 8(2):232. doi:10.3390/jcm8020232.
[13]	Walsh KF, Mcaulay K, Lee MH, et al. Early Bactericidal Activity Trial of Nitazoxanide for Pulmonary Tuberculosis. Antimicrob Agents Chemother, 2020, 64(5):e01956-19. doi:10.1128/AAC.01956-19.
[14]	Schiebler M, Brown K, Hegyi K, et al. Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic killing of Mycobacterium tuberculosis through inositol depletion. EMBO Mol Med, 2015, 7(2): 127-139. doi:10.15252/emmm.201404137. pmid: 25535254
[15]	Stanley SA, Barczak AK, Silvis MR, et al. Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog, 2014, 10(2): e1003946. doi:10.1371/journal.ppat.1003946.
[16]	Boland R, Heemskerk MT, Forn-Cuni G, et al. Repurposing Tamoxifen as Potential Host-Directed Therapeutic for Tuberculosis. mBio, 2023, 14(1): e0302422. doi:10.1128/mbio.03024-22.
[17]	Ouyang Q, Zhang K, Lin D, et al. Bazedoxifene Suppresses Intracellular Mycobacterium tuberculosis Growth by Enhancing Autophagy. mSphere, 2020, 5(2):e00124-20. doi:10.1128/mSphere.00124-20.
[18]	Chung C, Silwal P, Kim I, et al. Vitamin D-Cathelicidin Axis: at the Crossroads between Protective Immunity and Pathological Inflammation during Infection. Immune Netw, 2020, 20(2): e12. doi:10.4110/in.2020.20.e12.
[19]	Juarez E, Carranza C, Sanchez G, et al. Loperamide Restricts Intracellular Growth of Mycobacterium tuberculosis in Lung Macrophages. Am J Respir Cell Mol Biol, 2016, 55(6): 837-847. doi:10.1165/rcmb.2015-0383OC.
[20]	Abate G, Ruminiski PG, Kumar M, et al. New Verapamil Analogs Inhibit Intracellular Mycobacteria without Affecting the Functions of Mycobacterium-Specific T Cells. Antimicrob Agents Chemother, 2015, 60(3): 1216-1225. doi:10.1128/AAC.01567-15. pmid: 26643325
[21]	Hu S, He W, Du X, et al. Vitamin B1 Helps to Limit Mycobacterium tuberculosis Growth via Regulating Innate Immunity in a Peroxisome Proliferator-Activated Receptor-gamma-Dependent Manner. Front Immunol, 2018, 9: 1778. doi:10.3389/fimmu.2018.01778.
[22]	Zhang X, Ding G, Yang X, et al. Myriocin enhances the clea-rance of M.tuberculosis by macrophages through the activation of PLIN2. mSphere, 2024, 9(7):e0025724. doi:10.1128/msphere.00257-24.
[23]	Bohme J, Martinez N, Li S, et al. Metformin enhances anti-mycobacterial responses by educating CD8⁺ T-cell immunometabolic circuits. Nat Commun, 2020, 11(1): 5225. doi:10.1038/s41467-020-19095-z.
[24]	Singhal A, Jie L, Kumar P, et al. Metformin as adjunct antituberculosis therapy. Sci Transl Med, 2014, 6(263): 263ra159. doi:10.1126/scitranslmed.3009885.
[25]	Pahuja I, Verma A, Ghoshal A, et al. Biapenem, a Carbapenem Antibiotic, Elicits Mycobacteria Specific Immune Responses and Reduces the Recurrence of Tuberculosis. Microbiol Spectr, 2023, 11(4): e0085823. doi:10.1128/spectrum.00858-23.
[26]	Mayer-Barber KD, Andrade BB, Oland SD, et al. Host-directed therapy of tuberculosis based on interleukin-1 and type Ⅰ interferon crosstalk. Nature, 2014, 511(7507): 99-103. doi:10.1038/nature13489.
[27]	Vilaplana C, Marzo E, Tapia G, et al. Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J Infect Dis, 2013, 208(2): 199-202. doi:10.1093/infdis/jit152. pmid: 23564636
[28]	Mishra R, Krishan S, Siddiqui AN, et al. Potential role of adjuvant drugs on efficacy of first line oral antitubercular therapy: Drug repurposing. Tuberculosis (Edinb), 2020, 120: 101902. doi:10.1016/j.tube.2020.101902.
[29]	Sorgi CA, Soares EM, Rosada RS, et al. Eicosanoid pathway on host resistance and inflammation during Mycobacterium tuberculosis infection is comprised by LTB(4) reduction but not PGE2 increment. Biochim Biophys Acta Mol Basis Dis, 2020, 1866(3): 165574. doi:10.1016/j.bbadis.2019.165574.
[30]	Maitra A, Evangelopoulos D, Chrzastek A, et al. Carprofen elicits pleiotropic mechanisms of bactericidal action with the potential to reverse antimicrobial drug resistance in tuberculosis. J Antimicrob Chemother, 2020, 75(11): 3194-3201. doi:10.1093/jac/dkaa307. pmid: 32790867
[31]	Maiga M, Ammerman NC, Maiga MC, et al. Adjuvant host-directed therapy with types 3 and 5 but not type 4 phospho-diesterase inhibitors shortens the duration of tuberculosis treatment. J Infect Dis, 2013, 208(3): 512-519. doi:10.1093/infdis/jit187.
[32]	Maiga MC, Ahidjo BA, Maiga M, et al. Roflumilast, a Type 4 Phosphodiesterase Inhibitor, Shows Promising Adjunctive, Host-Directed Therapeutic Activity in a Mouse Model of Tuberculosis. Antimicrob Agents Chemother, 2015, 59(12): 7888-7890. doi:10.1128/AAC.02145-15. pmid: 26438491
[33]	Parihar SP, Guler R, Khutlang R, et al. Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. J Infect Dis, 2014, 209(5): 754-763. doi:10.1093/infdis/jit550. pmid: 24133190
[34]	Parihar SP, Guler R, Brombacher F. Statins: a viable candidate for host-directed therapy against infectious diseases. Nat Rev Immunol, 2019, 19(2): 104-117. doi:10.1038/s41577-018-0094-3. pmid: 30487528
[35]	Safe IP, Amaral EP, Araujo-Pereira M, et al. Adjunct N-Acetylcysteine Treatment in Hospitalized Patients With HIV-Associated Tuberculosis Dampens the Oxidative Stress in Peripheral Blood: Results From the RIPENACTB Study Trial. Front Immunol, 2020, 11: 602589. doi:10.3389/fimmu.2020.602589.
[36]	Shankaran D, Singh A, Dawa S, et al. The antidepressant sertraline provides a novel host directed therapy module for augmenting TB therapy. Elife, 2023, 12:e64834. doi:10.7554/eLife.64834.
[37]	Skerry C, Harper J, Klunk M, et al. Adjunctive TNF inhibition with standard treatment enhances bacterial clearance in a murine model of necrotic TB granulomas. PLoS One, 2012, 7(6): e39680. doi:10.1371/journal.pone.0039680.
[38]	Maiga M, Ahidjo BA, Maiga MC, et al. Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis. EBioMedicine, 2015, 2(8): 868-873. doi:10.1016/j.ebiom.2015.07.014. pmid: 26425693
[39]	Young C, Walzl G, Du Plessis N. Therapeutic host-directed strategies to improve outcome in tuberculosis. Mucosal Immunol, 2020, 13(2): 190-204. doi:10.1038/s41385-019-0226-5. pmid: 31772320
[40]	Chandra P, Grigsby SJ, Philips JA. Immune evasion and provo-cation by Mycobacterium tuberculosis. Nat Rev Microbiol, 2022, 20(12): 750-766. doi:10.1038/s41579-022-00763-4.
[41]	Orme IM, Robinson RT, Cooper AM. The balance between protective and pathogenic immune responses in the TB-infected lung. Nat Immunol, 2015, 16(1): 57-63. doi:10.1038/ni.3048. pmid: 25521685
[42]	Ernst JD. Mechanisms of M.tuberculosis Immune Evasion as Challenges to TB Vaccine Design. Cell Host Microbe, 2018, 24(1): 34-42. doi:10.1016/j.chom.2018.06.004. pmid: 30001523
[43]	Oehlers SH, Cronan MR, Beerman RW, et al. Infection-Induced Vascular Permeability Aids Mycobacterial Growth. J Infect Dis, 2017, 215(5): 813-817. doi:10.1093/infdis/jiw355. pmid: 27496976
[44]	Miow QH, Vallejo AF, Wang Y, et al. Doxycycline host-directed therapy in human pulmonary tuberculosis. J Clin Invest, 2021, 131(15):e141895. doi:10.1172/JCI141895.
[45]	Flynn JL, Chan J. Immune cell interactions in tuberculosis. Cell, 2022, 185(25): 4682-4702. doi:10.1016/j.cell.2022.10.025. pmid: 36493751
[46]	Bo H, Moure UAE, Yang Y, et al. Mycobacterium tuberculosis-macrophage interaction: Molecular updates. Front Cell Infect Microbiol, 2023, 13: 1062963. doi:10.3389/fcimb.2023.1062963.
[47]	Ersahin T, Tuncbag N, Cetin-Atalay R. The PI3K/AKT/mTOR interactive pathway. Mol Biosyst, 2015, 11(7): 1946-1954. doi:10.1039/c5mb00101c. pmid: 25924008
[48]	Kinsey CG, Camolotto SA, Boespflug AM, et al. Protective autophagy elicited by RAF—>MEK—>ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat Med, 2019, 25(4): 620-627. doi:10.1038/s41591-019-0367-9. pmid: 30833748
[49]	Sui X, Kong N, Ye L, et al. p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents. Cancer Lett, 2014, 344(2): 174-179. doi:10.1016/j.canlet.2013.11.019. pmid: 24333738
[50]	Yang L, Wu Y, Lin S, et al. sPLA2-IB and PLA2R mediate insufficient autophagy and contribute to podocyte injury in idiopathic membranous nephropathy by activation of the p38MAPK/mTOR/ULK1(ser757) signaling pathway. FASEB J, 2021, 35(2): e21170. doi:10.1096/fj.202001143R.
[51]	Kim SY, Yang CS, Lee HM, et al. ESRRA (estrogen-related receptor alpha) is a key coordinator of transcriptional and post-translational activation of autophagy to promote innate host defense. Autophagy, 2018, 14(1): 152-168. doi:10.1080/15548627.2017.1339001.
[52]	文章新, 刘红, 盛志峰, 等. 维生素D及其受体对糖尿病肾病保护作用的研究进展. 中国医师杂志, 2021, 23(12):1901-1904. doi:10.3760/cma.j.cn431274-20200907-01247.
[53]	Fabri M, Stenger S, Shin DM, et al. Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages. Sci Transl Med, 2011, 3(104): 104ra102. doi:10.1126/scitranslmed.3003045.
[54]	Adams KN, Verma AK, Gopalaswamy R, et al. Diverse Clinical Isolates of Mycobacterium tuberculosis Develop Macrophage-Induced Rifampin Tolerance. J Infect Dis, 2019, 219(10): 1554-1558. doi:10.1093/infdis/jiy710.
[55]	Adams KN, Szumowski JD, Ramakrishnan L. Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs. J Infect Dis, 2014, 210(3): 456-466. doi:10.1093/infdis/jiu095. pmid: 24532601
[56]	Lake MA, Adams KN, Nie F, et al. The human proton pump inhibitors inhibit Mycobacterium tuberculosis rifampicin efflux and macrophage-induced rifampicin tolerance. Proc Natl Acad Sci U S A, 2023, 120(7): e2215512120. doi:10.1073/pnas.2215512120.
[57]	Guirado E, Rajaram MV, Chawla A, et al. Deletion of PPARgamma in lung macrophages provides an immunoprotective response against M.tuberculosis infection in mice. Tuberculosis (Edinb), 2018, 111: 170-177. doi:10.1016/j.tube.2018.06.012.
[58]	Sutter A, Landis D, Nugent K. Metformin has immunomodulatory effects which support its potential use as adjunctive therapy in tuberculosis. Indian J Tuberc, 2024, 71(1): 89-95. doi:10.1016/j.ijtb.2023.05.011. pmid: 38296396
[59]	Singh DK, Dwivedi VP, Ranganathan A, et al. Blockade of the Kv1.3 K⁺ Channel Enhances BCG Vaccine Efficacy by Expanding Central Memory T Lymphocytes. J Infect Dis, 2016, 214(9): 1456-1464. doi:10.1093/infdis/jiw395.
[60]	Pires D, Valente S, Calado M, et al. Repurposing Saquinavir for Host-Directed Therapy to Control Mycobacterium Tuberculosis Infection. Front Immunol, 2021, 12: 647728. doi:10.3389/fimmu.2021.647728.
[61]	Cicchese JM, Evans S, Hult C, et al. Dynamic balance of pro- and anti-inflammatory signals controls disease and limits pathology. Immunol Rev, 2018, 285(1): 147-167. doi:10.1111/imr.12671. pmid: 30129209
[62]	Zumla A, Rao M, Dodoo E, et al. Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis. BMC Med, 2016, 14: 89. doi:10.1186/s12916-016-0635-1. pmid: 27301245
[63]	Gupta A, Misra A, Deretic V. Targeted pulmonary delivery of inducers of host macrophage autophagy as a potential host-directed chemotherapy of tuberculosis. Adv Drug Deliv Rev, 2016, 102: 10-20. doi:10.1016/j.addr.2016.01.016.
[64]	Van Toorn R, Zaharie SD, Seddon JA, et al. The use of thalidomide to treat children with tuberculosis meningitis: A review. Tuberculosis (Edinb), 2021, 130: 102125. doi:10.1016/j.tube.2021.102125.
[65]	申晓娜, 姚岚. 结核病宿主导向治疗研究进展. 同济大学学报(医学版), 2019, 40(1):123-127. doi:10.16118/j.1008-0392.2019.01.023.